Article
type: Class

Document
type: Class

2018
type: Class

Anualidad
type: Class

Academic Article
type: Class

Information Content Entity
type: Class

Continuant
type: Class

Entity
type: Class

Generically Dependent Continuant
type: Class

individual
type: Document
rights: termsOfUse
date: 2026-08-29T18:38:54
publisher: Combination Therapy with GLP-1 Receptor Agonists and SGLT-2 Inhibitors in Older Patients with Type 2 Diabetes: a Real-World Evidence Study
label: RDF description of Combination Therapy with GLP-1 Receptor Agonists and SGLT-2 Inhibitors in Older Patients with Type 2 Diabetes: a Real-World Evidence Study - http://research.umh.es/vivo/pub/articulo/193930

Combination Therapy with GLP-1 Receptor Agonists and SGLT-2 Inhibitors in Older Patients with Type 2 Diabetes: a Real-World Evidence Study
type: 2018
has publication venue: CANADIAN JOURNAL OF DIABETES
ARG_2000028: 193930 vcard
type: Academic Article
type: Thing
type: Generically Dependent Continuant
type: Information Content Entity
included: Medicina Clínica 2018
most specific type: 2018
type: Anualidad
date time value: 193930 pubdate
type: Continuant
type: Article
type: Document
type: Entity
related by: Autor:50289-Artículo:193930
most specific type: Academic Article

CANADIAN JOURNAL OF DIABETES
type: Information Content Entity
type: Journal
type: Collection
type: Generically Dependent Continuant
type: Entity
type: Continuant
type: Thing
publication venue for: Combination Therapy with GLP-1 Receptor Agonists and SGLT-2 Inhibitors in Older Patients with Type 2 Diabetes: a Real-World Evidence Study
type: Periodical

Medicina Clínica 2018
type: Anualidad
type: 2018
type: DepartmentReport
type: Thing
type: ResearchReport
includes: Combination Therapy with GLP-1 Receptor Agonists and SGLT-2 Inhibitors in Older Patients with Type 2 Diabetes: a Real-World Evidence Study

Autor:50289-Artículo:193930
type: Relationship
type: BFO_0000020
type: Entity
type: Thing
type: Authorship
type: Continuant
relates: Combination Therapy with GLP-1 Receptor Agonists and SGLT-2 Inhibitors in Older Patients with Type 2 Diabetes: a Real-World Evidence Study